Online ISSN: 2149-3189
2015
Monthly
Nicaea Medical Publishing
Türkiye

Fifteen-year treatment of metastatic thyroid medullary carcinoma: a case report

Ozen Oz Gul, Soner Cander, Pinar Sisman, Erdinc Erturk, Canan Ersoy
  • Ozen Oz Gul (Author) Department of Endocrinology and Metabolism, Uludag University Medical School, Bursa
  • Soner Cander (Author) Department of Endocrinology and Metabolism, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa
  • Pinar Sisman (Author) Department of Endocrinology and Metabolism, Uludag University Medical School, Bursa
  • Erdinc Erturk (Author) Department of Endocrinology and Metabolism, Uludag University Medical School, Bursa
  • Canan Ersoy (Author) Department of Endocrinology and Metabolism, Uludag University Medical School, Bursa
DOI
https://doi.org/10.18621/eurj.2015.1.3.160
Abstract
Although very rare, medullary thyroid carcinoma (MTC) is the most aggressive in differentiated thyroid malignancies. We report a 48-year-old male patient with the diagnosis of MTC, who was monitored for fifteen years and showed no serious adverse events due to long-term chemotherapy. Total thyroidectomy, neck dissection, retrosternal nodule excision and pericardiectomy were performed, and radiotherapy was applied to the neck area. Due to progressive metastatic disease cyclophosphamide, dacarbazine, and vincristine were administrated. He tolerated chemotherapy well, and no severe systemic side effects were detected. He died due to multi-organ failure after fifteen years of diagnosis. The only curative treatment is surgery in MTC, however; radiotherapy, chemotherapy, and embolization may be used for patients for whom surgery cannot be performed. Although success rates of systemic chemotherapy are low, it is a treatment option in the progressive metastatic disease.
Keywords
Medullary thyroid carcinoma, metastatic, chemotherapy, thyroid cancer
References

de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev. 2006 Aug;27(5):535-60.

Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71.

Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005 Jun;15:531-44.

Moley J. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Canc Netw. 2010 May;8(5):549-56

Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999 Jun;229(6):880-7; discussion 887-8.

Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. J Intern Med. 2003 Jun;253(6):616-26.

Meijer JA, Bakker LE, Valk GD, de Herder WW, de Wilt JH, Netea-Maier RT, et al. Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study. Eur J Endocrinol. 2013 Apr 15;168(5):779-86.

Orlandi F, Caraci P, Mussa A, Saggiorato E, PancaniG, Angeli A. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer. 2001 Jun;8(2):135-47.

Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hichey RC, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore). 1984 Nov;63(6):319-42.

Shimaoka K, Schoenfield DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985 Nov 1;56(9):2155-60.

Kelson DP, Cheng E, Kemeny N, Magill GB, Yagoda A. Streptozotocin and adriamycin in the treatment of APUD tumors (carcinoid, islet cell and medullary carcinoma of the thyroid). Proc Am Assoc Cancer Res. 1982;13:111.

Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP 3rd. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer. 1994 Jan 15;73(2):432-6.

Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2008 Jan;8(1):83-95.

Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009 Jan;9(1):28-39.

Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE, Group d’Etude des Tumeurs a´ Calcitonine (GETC). Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5FU-dacarbazine. Br J Cancer. 1995 Feb;71(2):363-5.

Deutschbein T, Matuszczyk A, Moeller LC, Unger N, Yuece A, Lahner H, et al. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine: a single-center experience. Exp Clin Endocrinol Diabetes. 2011 Oct;119(9):540-3.

There are 16 references in total.
How to Cite
1.
Oz Gul O, Cander S, Sisman P, Erturk E, Ersoy C. Fifteen-year treatment of metastatic thyroid medullary carcinoma: a case report. Eur Res J. 2015;1(3):160-164. doi:10.18621/eurj.2015.1.3.160
License
Creative Commons License

Copyright (c) 2015 The European Research Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

View Vol. 1 No. 3 (2015)

Vol. 1 No. 3 (2015)

Article Information

  • Article Type Case Report
  • Submitted February 21, 2026
  • Published November 3, 2015
  • Issue Vol. 1 No. 3 (2015)
  • Section Case Report
  • File Downloads 1245
  • Abstract Views 594
  • Altmetrics
  • Share
Download data is not yet available.